trial

10-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals

NCTId NCT03090490
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Unknown
Enrollment 68 (estimated)
Sponsored by Fundación Marques de Valdecilla
Primary completion 2017-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Unknown
Enrollment
68 (estimated)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
None
Start
2014-09
Primary completion
2017-12
Eligibility
ALL · 15 Years · 60 Years

Interventions & indications

Drugs
Antipsychotic treatment discontinuationAripiprazole

Sponsors

Fundación Marques de ValdecillaLead Sponsor
Centro de Investigación Biomédica en Red de Salud MentalCollaborator
Instituto de Investigación Marqués de ValdecillaCollaborator

Investigators

1
Benedicto Crespo-Facorro, ProfessorPrincipal Investigator

Sites

1 total
Santander, Spain

Facts & assertions

4 sourced
Enrollment
68
Phase
NA
Primary Completion Date
2017-12
Status
UNKNOWN
relationships
The graph out of here
drug
Antipsychotic treatment discontinuation
drug
Aripiprazole
drug
lead_sponsor
Fundación Marques de Valdecilla
company
collaborator
Centro de Investigación Biomédica en Red de Salud Mental
company
Instituto de Investigación Marqués de Valdecilla
company
indication
Schizophrenia Spectrum and Other Psychotic Disorders
indication
Schizophrenia Spectrum and Other Psychotic Disorders
indication
Schizophrenia
indication
investigator
Benedicto Crespo-Facorro, Professor
person